ATLANTA, Jan. 4 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., President and Chief Executive Officer, will present a company overview and update at the 24th Annual JPMorgan Healthcare Conference on Monday, January 9, 2006, at 11:30 a.m. PST (2:30 p.m. EST) at the Westin St. Francis Hotel in San Francisco, California.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO)
A live audio webcast of the presentation will be available via a link on the Company’s Investor Relations website at http://www.atherogenics.com, under “Investor Calendar.” A replay of the presentation will be available for 14 days.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics’ lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.
AtheroGenics, Inc.
CONTACT: Donna Glasky, Corporate Communications of AtheroGenics, Inc.,+1-678-336-2517, or email investor@atherogenics.com; or Investor Relations,Lilian Stern of Stern Investor Relations, +1-212-362-1200, or emaillilian@sternir.com; or Media Relations, Katie Brazel of Fleishman Hillard,+1-404-739-0150, or email brazelk@fleishman.com
Web site: http://www.atherogenics.com//
